Opus Genetics Extends Cash Runway to 2029, Advances Multiple Gene Therapies to Pivotal Trials

summarizeSummary

Opus Genetics announced Q1 2026 financial results, extending its cash runway into 2029 and reporting significant clinical progress for its gene therapy pipeline, including positive data for OPGx-LCA5 and upcoming data for OPGx-BEST1.

check_boxKey Events · Financing and Capital Events · IRD

• Extended Cash Runway to 2029

  Opus Genetics now expects its cash resources, including a recent $35 million funding and a $5 million equity investment from Oberland Capital, to fund operations into 2029.

• Positive OPGx-LCA5 Clinical Data

  The company presented positive six-month pediatric cohort data for OPGx-LCA5 at ARVO 2026, showing robust and consistent improvements in cone-mediated function.

• FDA RDEP Acceptance for OPGx-LCA5

  The FDA granted acceptance of the OPGx-LCA5 program into its Rare Disease Evidence Principles (RDEP) program, providing guidance for demonstrating effectiveness.

• OPGx-LCA5 Pivotal Phase 3 Trial Progression

  Recruitment is ongoing for the pivotal Phase 3 trial for OPGx-LCA5, with dosing expected to commence in the fourth quarter of 2026.

auto_awesomeAnalysis · IRD · Life Sciences

This filing is highly important because Opus Genetics has significantly strengthened its financial position, extending its cash runway into 2029. This provides substantial stability for a clinical-stage biotech, de-risking its operations for the medium term. Concurrently, the company reported positive clinical data for its OPGx-LCA5 program, which has also received FDA RDEP acceptance and is progressing to a pivotal Phase 3 trial. These developments collectively validate its pipeline and set the stage for multiple clinical inflection points.